Background: Schizophrenia is a psychiatric disorder whose therapeutic objectives are aimed at reducing symptoms and improving patient's quality of life. First- and second-generation antipsychotics present numerous side effects. Recently introduced in the treatment of schizophrenia, cariprazine has shown to improve positive and negative symptoms as well as cognitive impairment, with good tolerability.
Objective: To assess the level of consensus among Italian psychiatrists in relation to the use of cariprazine in the treatment of schizophrenia by using the Delphi technique.
Method: A Delphi study was undertaken between January and July 2022. Two questionnaires were consecutively sent to a panel of 97 psychiatrists from all over Italy, of which 81 actively participated, anonymously, in at least one of the two consultations with a sufficiently high response rate (83%).
Results: Broad consensus in terms of the efficacy and safety of cariprazine in the treatment of schizophrenia during all phases of the disorder. The young first-episode schizophrenia patient with or without substance abuse seems to be an excellent candidate for cariprazine therapy. In addition, the lack of side effects makes cariprazine a suitable drug for adult and elderly patients with schizophrenia. However, there is still limited experience with the use of cariprazine, along with little knowledge of the most recent real-life data.
Conclusion: These results could encourage wider dissemination of evidence-based practices with the final aim of optimizing the clinical use of cariprazine in patients with schizophrenia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556386 | PMC |
| http://dx.doi.org/10.2174/1570159X21666230719162023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of antipsychotics on the focal adhesion pathway.
World J Biol Psychiatry
January 2025
School of Medicine, IMPACT, Institute for Innovation in Physical and Mental Health and Clinical Translation, Deakin University, Geelong, Australia.
Unlabelled: Focal adhesions and their dynamic nature are essential for various physiological processes, including the formation of neurites, synaptic function and plasticity. Alterations in these processes have been associated with schizophrenia and bipolar disorder.
Objectives: This study aimed to explore the impact of pharmacological treatments used for bipolar disorder and schizophrenia on the expression of genes involved in the focal adhesion pathway, addressing a gap in understanding the interaction between medication effects and disease pathophysiology.
Gut mycobiome and neuropsychiatric disorders: insights and therapeutic potential.
Front Cell Neurosci
January 2025
Reserach Unit "Drosophila"UR22ES03, Faculty of Medicine, University of Sfax, Sfax, Tunisia.
Background: The human gut mycobiome, a minor but integral component of the gut microbiome, has emerged as a significant player in host homeostasis and disease development. While bacteria have traditionally been the focus of gut microbiome studies, recent evidence suggests that fungal communities (mycobiota) may also play a crucial role in modulating health, particularly in neuropsychiatric disorders.
Objective: This review aims to provide a comprehensive overview of current knowledge on the relationship between the gut mycobiome and neuropsychiatric disorders, exploring the potential of targeting fungal communities as a novel therapeutic strategy.
Can an Acceptance and Commitment Therapy-Based Smartphone App Help Individuals with Mental Health Disorders Quit Smoking?
Depress Anxiety
January 2025
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Background: Individuals with mental health disorders face major barriers in accessing smoking cessation care, often due to the stigmas associated with mental disorders and addiction. Consequently, accessible population-based smoking cessation interventions are needed for this vulnerable group.
Objective: This secondary analysis utilized data from a 12-month randomized trial to examine whether an acceptance and commitment therapy-based app (iCanQuit) demonstrated greater efficacy, engagement, and satisfaction compared to a United States (US) Clinical Practice Guidelines-based app (QuitGuide) in helping adults with mental health disorders quit smoking.
Metacognition and epistemic injustice in schizophrenia.
Front Psychiatry
January 2025
Department of Cognitive Science, Institute of Information and Communication Research, Nicolaus Copernicus University in Toruń, Toruń, Poland.
Basic self-disorders may play a role in the development of depression in schizophrenia: a seven-year follow-up study.
Front Psychiatry
January 2025
Adult Psychiatry Department, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Introduction: Depression is the most common co-morbid psychiatric disorder in patients with schizophrenia and has a negative effect on functional outcomes and quality of life. There are several possible pathways leading to depressive symptoms in schizophrenia. Self-disorders are disturbances in the deepest, pre-reflective level of the self and are suggested to be core features of schizophrenia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!